Fig. 7

In vivo pharmacokinetic, biodistribution, and antitumor efficacy. A Plasma concentration–time profiles of Dox in rats following i.v. administration of Dox•HCl, Dox@GNCs, and B7H3/Dox@GNCs at a Dox dose of 3 mg/kg. B Biodistribution profiles of Dox in tumor tissues of NSCLCs tumor-bearing mice following intravenous injection of Dox·HCl, Dox@GNCs, and B7H3/Dox@GNCs at Dox dose of 3 mg/kg for different time. C Body weight changes, D Tumor volume changes, and E Tumor tissue photo of saline, GNCs, Dox•HCl, B7H3/Dox@GNCs and B7H3/Dox@GNCs with NIR irradiation of tumor-bearing mice during the 14 day treatment or at the 14th day. F H&E and CD34 sained of the the tissues including heart, liver, spleen, lung, kidney, and tumor from NSCLCs xenograft-bearing mice after intravenous administration of saline, GNCs, Dox•HCl, B7H3/Dox@GNCs and B7H3/Dox@GNCs with NIR irradiation. Data are Mean ± SD (n = 3), ^*P < 0.05 and ^**P < 0.01, (one-sample t-test) versus Dox group